๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

New Concepts in the Pathogenesis, Diagnosis, Prognostic Factors and Clinical Presentation of Chronic Lymphocytic Leukemia

โœ Scribed by Michael Hallek

Book ID
114432694
Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
151 KB
Volume
4
Category
Article
ISSN
1127-0020

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The GNAS1 T393C polymorphism and lack of
The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia
โœ Mohd Arifin Kaderi; Fiona Murray; Mattias Jansson; Mats Merup; Karin Karlsson; G ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 230 KB

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with no known single predisposing genetic factor shown in all cases. Recently, a single nucleotide polymorphism (SNP) T393C in the GNAS1 gene has been reported to have a clinical impact on CLL progression and overall survival.

Subcutaneous Alemtuzumab in Fludarabine-
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
โœ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› American Society of Clinical Oncology ๐ŸŒ English โš– 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients